CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
rhuFab V2 (ranibizumab)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00056836
NCT00056836Phase 3Completed
CompareCT.gov

A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration

Genentech, Inc.·interventional·Posted Mar 26, 2003·Updated May 16, 2014

In Brief

A Phase 3 clinical trial evaluating rhuFab V2 (ranibizumab) for Macular Degeneration. Completed.

Detailed Summary

The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 26, 2003
Enrollment StartMar 1, 2003
Study CompletionDec 1, 2005
TodayJul 2, 2026
Posted 23.3 years ago

Interventions

rhuFab V2 (ranibizumab)drug